Antonio Frassoldati Selected Research

Antonio Frassoldati Research Topics

Disease

52	Breast Neoplasms (Breast Cancer) 11/2023 - 07/2003
29	Neoplasms (Cancer) 10/2023 - 02/2002
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 11/2018
5	Disease Progression 06/2023 - 07/2015
4	Colorectal Neoplasms (Colorectal Cancer) 08/2021 - 07/2012
3	Carcinoma (Carcinomatosis) 02/2024 - 07/2015
3	Neoplasm Metastasis (Metastasis) 10/2023 - 01/2019
3	Brain Neoplasms (Brain Tumor) 09/2023 - 01/2019
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2022 - 01/2020
3	Cardiotoxicity 01/2016 - 05/2009
2	Inflammation (Inflammations) 06/2023 - 01/2019
2	Liver Neoplasms (Liver Cancer) 12/2022 - 09/2022
2	Hepatocellular Carcinoma (Hepatoma) 09/2022 - 03/2018
2	Renal Cell Carcinoma (Grawitz Tumor) 06/2022 - 01/2019
2	Prostatic Neoplasms (Prostate Cancer) 06/2022 - 01/2022
2	Lung Neoplasms (Lung Cancer) 03/2022 - 11/2018
2	Colonic Neoplasms (Colon Cancer) 08/2021 - 05/2010
2	Pathologic Complete Response 01/2021 - 02/2008
2	Stomatitis 01/2018 - 01/2017
2	Melanoma (Melanoma, Malignant) 06/2015 - 02/2012
1	Fallopian Tube Neoplasms 02/2024
1	Ovarian Neoplasms (Ovarian Cancer) 02/2024
1	Drug-Related Side Effects and Adverse Reactions 02/2024
1	Residual Neoplasm 11/2023
1	Malnutrition (Nutritional Deficiencies) 06/2023
1	Cachexia 06/2023
1	Adenocarcinoma of Lung 08/2022
1	Carcinogenesis 08/2021

Drug/Important Bio-Agent (IBA)

18	Hormones (Hormone)IBA 05/2023 - 01/2007
15	Trastuzumab (Herceptin)FDA Link 11/2023 - 04/2008
9	Biomarkers (Surrogate Marker)IBA 11/2023 - 02/2008
8	Letrozole (Femara)FDA LinkGeneric 11/2022 - 07/2003
8	NivolumabIBA 06/2021 - 11/2018
7	Aromatase InhibitorsIBA 10/2023 - 07/2003
7	exemestane (Aromasin)FDA Link 11/2018 - 07/2003
6	Lapatinib (GW572016)FDA Link 01/2021 - 02/2008
5	ErbB Receptors (EGF Receptor)IBA 01/2021 - 02/2008
5	AnthracyclinesIBA 11/2020 - 08/2005
4	Paclitaxel (Taxol)FDA LinkGeneric 02/2024 - 07/2008
4	Phenobarbital (Luminal)FDA Link 09/2023 - 04/2016
4	palbociclibIBA 12/2022 - 01/2018
4	Cell-Free Nucleic AcidsIBA 08/2022 - 12/2018
4	Immune Checkpoint InhibitorsIBA 03/2022 - 11/2018
4	human ERBB2 proteinIBA 02/2022 - 06/2012
4	Tamoxifen FDA LinkGeneric 10/2021 - 01/2007
4	MicroRNAs (MicroRNA)IBA 08/2021 - 01/2015
4	Everolimus FDA Link 11/2018 - 01/2017
4	Epirubicin (Ellence)FDA LinkGeneric 05/2009 - 08/2005
3	Proteins (Proteins, Gene)FDA Link 06/2023 - 08/2021
3	LigandsIBA 06/2022 - 05/2010
3	Anastrozole (Arimidex)FDA LinkGeneric 01/2018 - 07/2003
2	Carboplatin (JM8)FDA LinkGeneric 02/2024 - 03/2022
2	PlatinumIBA 02/2024 - 03/2022
2	Estrogen ReceptorsIBA 10/2023 - 10/2018
2	RNA (Ribonucleic Acid)IBA 03/2023 - 08/2022
2	Epidermal Growth Factor (EGF)IBA 11/2022 - 09/2015
2	AntigensIBA 06/2022 - 01/2015
2	Bevacizumab (Avastin)FDA Link 03/2022 - 01/2021
2	atezolizumabIBA 03/2022 - 06/2019
2	Estrogens (Estrogen)FDA Link 02/2022 - 01/2022
2	pertuzumabIBA 01/2022 - 01/2018
2	130-nm albumin-bound paclitaxelIBA 07/2021 - 01/2020
2	pembrolizumabIBA 06/2021 - 06/2019
2	taxaneIBA 11/2020 - 06/2012
2	Monoclonal AntibodiesIBA 05/2020 - 10/2008
2	Fulvestrant (Faslodex)FDA Link 02/2020 - 01/2018
2	Gefitinib (Iressa)FDA Link 09/2019 - 07/2008
2	Cetuximab (Erbitux)FDA Link 11/2016 - 07/2012
2	Fluorouracil (Carac)FDA LinkGeneric 10/2008 - 08/2005
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2008 - 08/2005
1	Gemcitabine FDA Link 02/2024
1	liposomal doxorubicin (Doxil)FDA Link 02/2024
1	TrabectedinIBA 02/2024
1	Topotecan (Hycamtin)FDA LinkGeneric 02/2024
1	B7-H1 AntigenIBA 11/2023
1	Aromatase (CYP19)IBA 10/2023
1	N-acetyltalosaminuronic acid (NAT)IBA 10/2023
1	AlbuminsIBA 06/2023
1	Circular RNAIBA 03/2023
1	DNA (Deoxyribonucleic Acid)IBA 03/2023
1	Peptides (Polypeptides)IBA 03/2023
1	Heme (Haem)IBA 03/2023
1	ribociclibIBA 11/2022
1	Etoposide (VP 16)FDA LinkGeneric 03/2022
1	Progesterone FDA LinkGeneric 02/2022
1	Mucin-1 (CA 15-3 Antigen)IBA 02/2022
1	Glucose (Dextrose)FDA LinkGeneric 02/2022
1	fluoromethylcholineIBA 01/2022
1	Choline (Choline Chloride)IBA 01/2022
1	Messenger RNA (mRNA)IBA 06/2021
1	Biological FactorsIBA 11/2019
1	Tyrosine Kinase InhibitorsIBA 09/2019

Therapy/Procedure

32	Therapeutics 10/2023 - 02/2002
21	Drug Therapy (Chemotherapy) 02/2024 - 10/2005
5	Neoadjuvant Therapy 10/2023 - 04/2014
3	Adjuvant Chemotherapy 04/2022 - 08/2005
2	Radiotherapy 01/2021 - 11/2018
1	Immunomodulation 11/2023
1	Patient Readmission 06/2023
1	Immunotherapy 03/2022